Form PTO-	1449	U.S. DEPARTM	ENT OF COMMER	RCE -	ATTY. DOCKET NO	T		Page 1	-o f 1
(MODIFIED) PATENT AND TRADEMARK OFFICE			038602	SERIAL NO.					
DE	70				APPLICANT		. 09	/863,8 0	<u> </u>
INF	ORMAT	ION DISCLOSUR	E CITATION			colm Wilson	MOON et	al.	ENTE FB %
1857,	割				FILING DATE		GROUP A	RT UNIT -	D 0
FEB		everal sheets if nec	essary)		05/24/	2001		1684 8	2007
PENT 3 TH	AMILIE		U.S. PA	TEN	T DOCUMENTS		<u> </u>) 0 0 0 0
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME	CLASS	SUB- CLASS	FILING	DATE F
								+ APPRO	PRIATE
									
								ļ	
								<u></u>	<u> </u>
	L						<u> </u>		
	Г	DOOLINATAIT	FOREIGN	PATE	NT DOCUMENTS				
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB-	TRANSL	ATION
RA	A1	99/61422	12/02/1999	WO			CLASS	YES	NO
R4	A2	00/08202		wo					
RA	A3	01/90104		wo					
		OTUED DOOL							
		OTHER DOCU	MENTS (Includin	ig Aut	hor, Title, Date, Pe	rtinent Pages, E	tc.)		
									_
				· -					
									-
EXAMINER		1			DATE CONSIDER	ED			
150	been	X notes				יבט			
	INER: Í	nitial if citation of	onsidered, whe	ther	5/14/02 or not citation is	in conforma			
line th			conformance a	nd no	of not citation is of considered. In	clude any con	e with MP y of this fo	'EP 609; orm with	Draw
comm	iunicatio	n to applicant.				,	,	441611	HEAL

Form	PTO-1	449
------	-------	-----

U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO.

SERIAL NO.

(MODIFIED)

PATENT AND TRADEMARK OFFICE

038602/1153

09/863,804

APPLICANT

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

MOON et al.

FILING DATE

GROUP ART UNIT 1626

May 24, 2001

-1614-

			U.S. P	ATENT DOCUMENTS			
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
RA	A1	2968557	1/17/61	Burgandt et al.			
RI	A2	4002749	1/11/77	Rovnyak			
RA	А3	4053613	10/11/77	Rovnyak et al.			
PA	A4	4642309	2/10/87	Michel et al.			
RA	A 5	4826847	5/2/89	Michel et al.			
RA	A6	5051417	9/24/91	Nadler et al.			
A	A7	5124347	6/23/92	Connor et al.			
Z	A8	5196446	3/23/93	Levitzki et al.			
24	A9	5302606	4/12/94	Spada et al.			
R	A10	5322950	6/21/94	Sircar et al.			
PH	A11	5374652	12/20/94	Buzzetti et al.			
R	A12	5382593	1/17/95	Le Baut et al.			
74	A13	5389661	2/14/95	Sircar et al.			
PA.	A14	5397787	3/14/95	Buzzetti et al.			
Z4	A15	5409949	4/25/95	Buzzetti et al.			
P.	A16	5792783	8/11/98	Tang et al.			
Z	A17	5834504	11/10/98	Tang et al.			
A	A18	5849710	12/15/98	Battistini et al.			
PAI	A19	5880141	3/9/99	Tang et al.	-		
A,	A20	5883113	3/16/99	Tang et al.			
H	A21	5883116	3/16/99	Tang et al.			

002.680154v2 Liber Mocker 5/14102

Form PTO-14	49	U.S. DEPARTMEN	Т ОГ СОММЕ	RCE	ATTY. DOCKET NO		SERIAL NO).	
(MODIFIED) PATENT AND TRADEM		TENT AND TRADEMARK OFFICE		038602/1153		09/863,804			
				APPLICANT		1			
INFO	ORMATI	ON DISCLOSURE	CITATION			MOON 6	et al.		
					FILING DATE	_	GROUP AR	RT UNIT	
	(Use se	everal sheets if neces:	sary)		May 24, 2	:001		1626	
TR	A22	5886020	3/23/99	Tan	g et al.				
PA	A23	6133305	10/17/00	Tan	g et al.				
			FOREIGN PA	TENT	DOCUMENTS			1	RE
EXAMINER		DOCUMENT					SUB-	TRANS	LATION
INITIAL	REF	NUMBER	DATE	i	COUNTRY	CLASS	CLASS	YES	NO
KA	A24	91/13055	9/5/91		WO			-	
7	A25	92/07830	5/14/92		WO				
P	A26	92/20642	11/26/92		wo				
PI	A27	93/01182	1/21/93		wo			-	
PA.	A28	94/14808	7/7/94		wo				
21.	A29	95/01349	1/12/95		WO				
PA	A30	95/17181	6/29/95		WO				
2	A31	96/00226	1/4/96		WO				
PA	A32	96/16964	6/6/96		WO				
PA	A33	96/22976	8/1/95		WO				
Ph	A34	96/32380	10/17/96		wo				
PA	A35	96/40116	12/19/96		wo				
PA,	A36	97/25986	7/24/97		WO				
PA,	A37	98/07695	2/26/98		WO				
FA.	A38	98/24432	6/11/98		WO				
XA.	A39	98/38984	9/11/98		wo				
PA	A40	98/50356	11/12/98		wo				
PA	A41	99/10325	3/4/99		wo				
FA.	A42	99/52869	10/21/99		wo				
PH.	A43	99/61422	12/2/99		WO				
002.68015	4v2)								
	4	shen Anders	5/	1410	2				

Form PTO-14	149	U.S. DEPARTMEN	IT OF COMMERCE	ATTY, DOCKET NO.	· <u>-</u>	SERIAL NO	
(MODIFIED)		PATENT AND TRA	ADEMARK OFFICE	038602/115	53	09	/863,804
				APPLICANT			
INFO	ORMATI	ON DISCLOSURE	CITATION		MOON e	t al.	
				FILING DATE		GROUP AR	T UNIT
	(Use se	everal sheets if neces	sary)	May 24, 200)1		1626 1014
TR	A44	99/65869	12/23/99	WO			
H	A45	00/08202	2/17/00	WO		<u> </u>	
2/	A46	00/35906	6/22/00	WO			
PI	A47	00/35908	6/22/00	WO			
57	A48	00/35909	6/22/00	WO			
PA	A49	00/38519	7/6/00	WO			
24	A50	00/56709	9/28/00	WO			
PA	A51	01/60814	8/23/01	WO			
PA	A52	2159360	11/30/71	Germany			
24	A53	2159361	11/30/71	Germany			
24	A54	2159362	11/30/71	Germany			
ZA,	A55	2159363	11/29/71	Germany			
A	A56	2321656	4/28/73	Germany			
A	A57	3426419	1/23/86	Germany			
A	A58	0252713	9/12/1990	EP		_	
24	A59	0351213	1/17/90	EP			
PA	A60	0525472	2/3/93	EP			
271	A61	0632102	1/4/95	EP			
24.	A62	0662473	7/12/95	EP			
24	A63	0788890	8/13/97	EP			
XX.	A64	0769947	5/2/97	EP			
21	A65	0934931	8/11/99	EP			
21	A66	1082305 A1	3/14/01	EP			
XA.	A67	1398224	3/29/65	France			
XX	A68	1599772	8/1970	France			

002 680154VZ Lebeca Amelesan 5/14/02

Form PTO-1	449	U.S. DEPARTMEN	IT OF COMMERCE	ATTY. DOCKET NO.	West Control of the C	SERIAL NO	١.	
(MODIFIED)		PATENT AND TRA	ADEMARK OFFICE	038602/1	153	09	/863,804	
				APPLICANT		1		
INF	ORMAT	ION DISCLOSURE	CITATION		MOON 6	et al.		
			FILING DATE	FILING DATE		T UNIT		
	(Use s	everal sheets if neces	sary)	May 24, 20	001		1696 1614	
H	A69	2689397	10/8/93	France				
A	A70	809691	3/4/59	Great Britain				
PA	A71	835473	5/18/60	Great Britain				
ZA	A72	6229570	7/2/87	Japan				
Pi	A73	6239564	2/20/87	Japan			-	
PA	A74	63141955	6/14/88	Japan				_
PA	A75	558894	3/9/93	Japan			-	
BL	A76	2012634	9/20/91	Canada				
Z	A77	286870	5/11/67	Australia				
<i>y</i> — V		OTHER DOCL	JMENTS (Including	Author, Title, Date, Pertir	nent Pages, Etc	c.)		
A	A78			nts. 25[1]. Synthesis ar es," <u>Anticancer Research</u>				
RA	A79	Andreani et al., "Syn	thesis and cardiotor	nic activity of 2-indolinone	es," <u>Eur. J. Me</u> c	d. Chem. 25:18	37-190 (1990)
RA	A80	Andreani et al., "Syn 28:653-657 (1993) ®	thesis and cardiotor Elsevier, Paris	nic activity of 2-indolinone	es bearing pyric	dyl groups," <u>E</u>	ur. J. Med. C	hem.
RA	A81	Andreani et al., "Syn 27:167-170 (1992) ©	thesis and cardiotor Elsevier, Paris	ic activity of pyridylmeth	ylene-2-indolin	ones," <u>Eur. J.</u>	Med. Chem.	
PA	A82	Andreani et al., "Syn b]thiazolylmethylene	thesis and potential)-2-indolinones," <u>Eu</u>	coanthracyclinic activity r. J. Med. Chem. 32:919-	of substituted 3	3-(5-imidazo[2 Isevier, Paris	,1-	
A	A83	Andreani et al., "Syn	thesis of lactams wit	h potential cardiotonic a	ctivity," <u>Eur. J.</u>	Med. Chem. 2	8:825-829 (1	 1993)
94	A84	Andreani et al., "In V Research 48:727-72		vity of Pyridylmethylene-2	2-indolinones,"	<u>Arzneimittel-F</u>	orschung Dr	ug
PA	A85	Bahner and Brotherto	on, "9-(4-Aminobenz	ylidene)fluorenes," <u>J. Me</u>	ed. Chem. 12:7	22-723 (1969)		
R	A86	Bahner et al., "Benzylideneindenes with Oxygen Attached to the Indene Ring," J. Med. Chem. 12:721-722 (1969)						
ZA,	A87	Bamfield et al., "Diels	-Alder Reactions of	Oxindolylideneacetone,	' <u>J. Chem. Soc</u>	. (C) 1028-103	0 (1966) ©	
A	A88	Borsche et al., "Über Chem. 550:160-174 (sierte Systeme mit hetero	ocyclischen Rin	igen. XIII.," <u>Lie</u>	ebigs Ann.	

002.680154v2

Liber Anderson 5/14/02

Form PTO-14	149	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.		
(MODIFIED)		PATENT AND TRADEMARK OFFICE	038602/1153	09/863,804		
			APPLICANT			
INFORMATI		ION DISCLOSURE CITATION	МС	OON et al.		
			FILING DATE GROUP ART UNIT			
	(Use s	everal sheets if necessary)	May 24, 2001	1626 1 614		
A	A89	Buzzetti et al., "Cinnamamide Analogs as (1993)	Inhibitors of Protein Tyrosine Ki	nases," <u>II Farmaco</u> 48:615-636		
\mathbb{Z}	A90	Chatten et al., "Substituted Oxindoles. P Benzylideneindol-2(3 <i>H</i>)-ones," <u>J. Chem.</u>		of Substituted <i>trans</i> -3-		
A	A91	Coda et al., "(Z)- and (E)-Arylidene-1,3-d Carbonyl Stretching Frequencies," J. Che				
R	A92	Coda et al., "3-(4-methylbenzilidene)-1,3- Transactions 2 4:615-620 (1984) DATAB				
\mathbb{Z}	A93	Decodts et al., "Suicide inhibitors of prote lactams," Eur. J. Med. Chem 18: 107-111		thyl derivatives of some aromatic		
\mathbb{A}	A94	Desimoni et al., "Catalysis with Inorganic Cations. V ¹ Intramolecular Hetero Diels-Alder <i>versus</i> Ene Reactions Effect of Magnesium perchlorate on Chemoselectivity," <u>Tetrahedron</u> 52(36) 12009-12018 (1196) © Pergamon				
24	A95	Elliott and Rivers, "Reduction of Some O: Borohydride," <u>J. Med. Chem.</u> 29:2438-24		bstituted Oxindoles by Sodium		
PA	A96	Elliott et al., "1-methyl-2-(3-oxindolidenmed DATABASE CROSSFIRE, Beilstein Refe		anic Chemistry 29:2438-2440 (1964		
R	A97	Gazit et al., "Tyrphostins. 2. Heterocycli Inhibitors of EGF Receptor and ErbB2/ne Am. Clem. Soc.				
PA	A98	Hirao et al., "Rhodium-Catalyzed Carbon Tetrahedron Letters 36(35) 1995 ©Pergar	• • •	eses of 1,3-Dihydroindol-2-ones,"		
PA	A99	Hodges et al., "Chemical and biological p 46:2189-2194 (1968)	roperties of some oxindolidyl-3-n	nethines," <u>Canadian J. Chemistry</u>		
	A100	Howard, Harry R., "Lactam Derivatives,"	'U.S. Provisional Patent Application Number 60/015134			
RA	A101	Howard et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1 <i>H</i>)-benzimidazolone- a oxindole-1-acetic acids," <u>Eur. J. Med. Chem.</u> 27:779-789 (1992) © Elsevier, Paris				
PA .	A102	Katritzky et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)				
RA	A103	Kobayashi et al., "Anti-tumor Activity of Indole Derivatives," Yakugaku Zasshi 97:1033-1039 (1977)				
RA	A104	Kovac and Stetinova, "Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoxindoles," Chem. rvesu 30:484-492 (1976)				
A	A105	Levitzki and Gazit, "Tyrosine Kinase Inhit (1995)	oition: An Approach to Drug Deve	elopment," <u>Science</u> 267:1782-1788		

A100 is considered but is not to be primed 5/14/02 RA
002.680154v2 Liberth Linderson 5/14/02

Form PTO-14	149	U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	SERIAL NO.	
(MODIFIED) PATENT AND TRADEMARK OF		PATENT AND TRADEMARK OFFICE	038602/1153	09/863,804	
			APPLICANT		
INFO	ORMAT	ON DISCLOSURE CITATION	MOON 6	et al.	
			FILING DATE	GROUP ART UNIT	
	(Use s	everal sheets if necessary)	May 24, 2001	1614	
A	A106	Mariani et al., "Inhibition of angiogenesis Therapeutics - Proceedings of the Americ (March 1994)			
A	A107	Mohammadi et al., "Structures of the Tyro Complex with Inhibitors," <u>Science</u> 276:95			
R	A108	Neber and Röcker, "On the action of benz 56:1710-1716 (1923) (GERMAN AND EN		acetic acid (II)," <u>Chem. Ber.</u>	
PA	A109	Nodiff et al., "Antimalarial Phenanthrene of Chemical Abstracts, Vol. 83, abstract no.		ng 9-phenanthrenemethanols,"	
PA	A110	O'Sullivan and Rothery, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenic Clinica Chimica Acta 62:181-182 (1975) ©Elsevier Scientific Publishing Company			
RA	A111	Pavlenko et al., "Introduction of aminome Ukr Rsrs, Ser. B: Geol., Khim. Biol. Nauk		molecules," <u>Dopov. Akad. Nauk</u>	
PA	A112	Plowman et al., "Receptor Tyrosine Kinas	ses as Targets for Drug Intervention," [DN&P 7:334-339 (1994)	
24	A113	Quallich et al., Á General Oxindole Synth	esis," <u>J. Synthetic Organic Chemistry</u> :	51-51 (1993)	
24	A114	Schuchter et al., "Successful Treatment of (1991)	of Murine Melanoma with Bryostatin 1,	' <u>Cancer Research</u> 51:682-687	
A	A115	Shiraishi et al., "Specific inhibitors of Tyro Derivatives," <u>Biochemical and Biophysica</u>	osine-Specific Protein Kinase, Syntheti I <u>Research Communications</u> 147:322-	ic 4-Hydroxycinnamamide 328 (1987)® Academic Press	
A	A116	Shiraishi et al., "Specific Inhibitors of Tyro Derivatives in Vitro," Cancer Research 49		ties of 4-Hydroxycinnamamide	
PA	A117	Singh et al., "Indolinone Derivatives as Po (1989) copyright VEB Gustav Fischer Ver		ol. Mikrobiol. 144:105-109	
A	A118	Spada, et al., "Small molecule inhibitors of tyrosine kinase activity," Expert Opinion on Therapeutic Patents 5:805-817 (1995) Ashley Publications			
A	A119	Sun et al., "Design, Synthesis, and Evalumethylidenyl]indolin-2-ones as Inhibitors of Medicinal Chemistry 42: 5120-5130 (1999)	of VEGF, FGF, and PDGF Receptor T		
A	A120	Sun et al, "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," J. Med. Chem. 41:2588-2603 (1998) ©The American Chemical Society			
A	A121	Tacconi and Marinone, "Preparazione e c 38:1239-1244 (1968)	caratteristiche di alcuni 3-ossindolideno	derivati," <u>Ricerca Scientifica</u>	

002.680154v2

Lolan Anderson 5/14/02

Form PTO-1	449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.		
MODIFIED)		PATENT AND TRADEMARK OFFICE	038602/1153	09/863,804		
			APPLICANT			
INF	ORMAT	TION DISCLOSURE CITATION	МО	ON et al.		
			FILING DATE	GROUP ART UNIT		
	(Use s	several sheets if necessary)	May 24, 2001	1606 1614		
RA	A122	Tacconi et al., "(Z)- and (E)-3-Alkylidene- Transmission of the Inductive Effect to the	1,3-dihydroindol-2-ones: Influence e Carbonyl Group," <u>J.C.S. Perkin</u>	e of Configuration on the II 150-154 (1976)		
PA.	A123	Thompson et al., "Facile Dimerisation of 3 1835-1837 (1993)	B-Benzylideneindoline-2-thiones,"	J. Chem. Soc. Perkin Trans. (I)		
R	A124	Traxler, "Protein tyrosine kinase inhibitors 7(6):571-588 (1997) © Ashley Publications	in cancer treatment," Expert Opir Ltd.	nion on Therapeutic Patents		
RA	A125	Wahl et al., "3-benzilidene-5-methyl-1,3-di CROSSFIRE, Beilstein Reference No. 2-2	hydroindol-2-one," <u>Ann. Chim.</u> 35 1-00-00290	0 (1926), DATABASE		
A	A126	Wahl, Beilstein Reg. No. 191439, Bull. So	c. Chim. Fr., page 1038 (1909)			
	A127	Wahl, Beilstein Reg. No. 231732, Bull. Soc	c. Chim. Fr., pages 1035-1038 (1	909)		
	A128	Walker et al., "Synthesis of New 3-(Pyridyl Alkylaminoethyl)-2-indolinones. The Redu of 2-Indolinones," <u>J. Med. Chem.</u> 8:626-63	oction of Isoindogenides Nitro Co.	-(Piperidylmethyl)-, and 3-(β- mpounds, and Pyridines in a Serie		
2	A129	Wright et al., "Cyclic Hydroxamic Acids De	rived from Indole," <u>J. Am. Chem.</u>	Soc. 78:221-224 (1956)		
<u>Z</u>	A130	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," J. Cellular Physiology 152:448-457 (1992)				
24	A131	Zhang et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," Molecular Pharmacology 49:228-234 (1996) copyright The American Society for Pharmacology and Experimental Pharmaceutics				

Form PTO-14	49	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
(MODIFIED)		PATENT AND TRADEMARK OFFICE	038602-1153	09/863,804
			APPLICANT	
INFO	ORMATI	ON DISCLOSURE CITATION	Peng Ch	no TANG et al.
			FILING DATE	GROUP ART UNIT
	(Use s	everal sheets if necessary)	May 24, 2001	1626 1814
B	A132	Zhungietu et al., "Reaction of Indoles and abstract no. 111201 (1990)	2-Ketoindolines With Some Alde	hydes," <u>Chemical Abstracts</u> , Vol. 7
	A133	English Translation of Hungarian Patent N	No. 3899/92	
	A134	English Translation of German Patent No	o. 2159360 (Ref. No. A85)	
	A135	English Translation of German Patent No	. 2159361 (Ref. No. A86)	
	A136	English Translation of German Patent No	. 2159363 (Ref. No. A88)	
	A137	English Translation of German Patent No	. 2321656 (Ref. No. A89)	
	A138	English Translation of German Patent No	. 3426419 (Ref. No. A90)	
	A139	English Translation of European Patent N	lo. 580502 (Ref. No. A96)	
	A140	English Translation of European Patent N	lo. 632102 (Ref. No. A98)	
. "	A141	English Translation of French Patent No.	2689397 (Ref. No. A107)	
	A142	English Translation of Japanese Patent N	lo. 6229570 (Ref. No. A110)	
	A143	English Translation of Japanese Patent N	lo. 6239564 (Ref. No. A111)	
	A144	English Translation of Japanese Patent N	lo. 63141955 (Ref. No. A 112)	
	A145	English Translation of Japanese Patent N	lo. 558894 (Ref. No. A113)	
	A146	English Translation of German Patent No	. 878539 (Ref No. A84)	
	A147	English Translation of French Patent No.	1398224 (Ref. No. A105)	
	A148	English Translation of French Patent No.	1599772 (Ref. No. A106)	
EXAMINER		<u> </u>	DATE CONSIDERED	
Kil	eur j	Anderson	5/14/02	

* English translations of already considered documents (A85 -86,88-90,96,98,107,110-113,84, 105-106)
were considered but will not be printed. Ft 5/14/02

line through citation if not in conformance and not considered. Include any copy of this form with next

communication to applicant.